FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Millan

Research Profile

Living Beings

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Marie-Josèphe Salles; Mark J Millan; Jean-Michel Rivet; Jean-Antoine Girault; Denis Hervé; Sophie Longueville; Clotilde Mannoury La Cour
Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.
Martin Egeland; Mark J Millan; Elisabeth Mocaer; Xiaoqun Zhang; Per Svenningsson
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice.
Florence Serres; Trevor Sharp; Jean-Pierre Galizzi; Brian Lockhart; Jean-Michel Rivet; Marianne Rodriguez; Mark J Millan
Blockade of α2-adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: a combined qPCR, in situ hybridisation and immunocytochemistry study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Millan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marie-Josèphe Salles; Mark J Millan; Jean-Michel Rivet; Jean-Antoine Girault; Denis Hervé; Sophie Longueville; Clotilde Mannoury La Cour
Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.
Journal of neurochemistry 2013;125(4):532-44.
2012: Martin Egeland; Mark J Millan; Elisabeth Mocaer; Xiaoqun Zhang; Per Svenningsson
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice.
Journal of neurochemistry 2012;123(5):811-23.
2012: Florence Serres; Trevor Sharp; Jean-Pierre Galizzi; Brian Lockhart; Jean-Michel Rivet; Marianne Rodriguez; Mark J Millan
Blockade of α2-adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: a combined qPCR, in situ hybridisation and immunocytochemistry study.
Neuropharmacology 2012;63(6):992-1001.
2012: Chantevy Pou; Leigh A Stoddart; Clotilde Mannoury La Cour; Mark J Millan; Graeme Milligan
Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.
The Journal of biological chemistry 2012;287(12):8864-78.
2012: Anne Dekeyne; Benjamin Di Cara; Gunnar Flik; Kevin C F Fone; Alain Gobert; Gilbert Lavielle; Florence Loiseau; Mauricette Brocco; Raymond Cespuglio; Johnny S W Chan; Thomas I Cremers; Berend Olivier; Mariusz Papp; Jean-Michel Rivet; Florence Serres; Trevor Sharp; David J G Watson; Mark J Millan
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
The Journal of pharmacology and experimental therapeutics 2012;340(3):765-80.
2012: Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
The Journal of pharmacology and experimental therapeutics 2012;340(3):750-64.
2012: Pascal Fossat; Mark J Millan; Jérôme Dulong; Stéphane H R Oliet; Loredano Pollegioni; Jean-Michel Rivet; Silvia Sacchi; Ting Shi; Jonathan V Sweedler; Fabrice R Turpin; Jean-Pierre Mothet
Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex.
Cerebral cortex (New York, N.Y. : 1991) 2012;22(3):595-606.
2012: Mark J Millan; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Larry J Young
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.
Nature reviews. Drug discovery 2012;11(2):141-68.
2011: Alain Gobert; Francesca Parsons; Jean-Michel Rivet; Rodolphe Billiras; Mark J Millan
Simultaneous quantification of D- vs. L-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: differential modulation by N-methyl-D-aspartate (NMDA) and other pharmacological agents.
Journal of neuroscience methods 2011;202(2):143-57.
2011: Mark J Millan; Philippe Marin; Joël Bockaert; Benjamin Chanrion; Ralf JOckers; Maud Kamal; Marilyne Labasque; Clotilde Mannoury La Cour
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2011;14(6):768-83.
2011: Gabriella Aloisi; Elena Silvano; M Rossi; Mark J Millan; Roberto Maggio
Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
Neuropharmacology 2011;60(2-3):439-45.
2011: Clotilde Mannoury La Cour; Marie-Josèphe Salles; Valérie Pasteau; Mark J Millan
Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂and D₃ receptors.
Molecular pharmacology 2011;79(1):91-105.
2010: Elena Silvano; Mark J Millan; Clotilde Mannoury La Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.
Molecular pharmacology 2010;78(5):925-34.
2010: Mark J Millan; Jerry J Buccafusco; Florence Loiseau; David J G Watson; Emmanuel Decamp; Kevin C F Fone; Nitza Thomasson-Perret; Michael Hill; Elisabeth Mocaer; Jay S Schneider
The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2010;13(8):1035-51.
2010: Mark J Millan; Anne Dekeyne; Alain Gobert; Clotilde Mannoury La Cour; Mauricette Brocco; Jean-Michel Rivet; Benjamin Di Cara; Françoise Lejeune; Thomas I Cremers; Gunnar Flik; Trynke R de Jong; Berend Olivier; Guillaume De Nanteuil
S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010;20(9):599-621.
2010: Anne Amphoux; Mark J Millan; Alex Cordi; Heinz Bönisch; Vincent Vialou; Clotilde Mannoury La Cour; Delphine S Dupuis; Bruno GIROS; Sophie Gautron
Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human alpha 1- and alpha 2-adrenoceptor subtypes.
European journal of pharmacology 2010;634(1-3):1-9.
2009: Amélie Soumier; Mounira Banasr; Sylviane Lortet; Frédérique Masmejean; Nathalie Bernard; Lydia Kerkerian-Le Goff; Cecilia Gabriel; Mark J Millan; Elisabeth Mocaer; Annie Daszuta
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(11):2390-403.
2009: Anne Dekeyne; Mark J Millan
Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.
Psychopharmacology 2009;203(2):329-41.
2009: Alain Gobert; Mauricette Brocco; Anne Dekeyne; Benjamin Di Cara; Gaëlle Bouchez; Françoise Lejeune; Robert L Gannon; Mark J Millan
Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(4):1039-56.
2009: Florence Loiseau; Mark J Millan
Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009;19(1):23-33.
2008: Mauricette Brocco; Anne Dekeyne; Clotilde Mannoury La Cour; Manuelle Touzard; Sylvie Girardon; Sylvie Veiga; Guillaume De Nanteuil; Trynke R deJong; Berend Olivier; Mark J Millan
Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008;18(10):729-50.
2008: Mark J Millan; Philippe Marin; Joël Bockaert; Clotilde Mannoury la Cour
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions.
Trends in pharmacological sciences 2008;29(9):454-64.
2008: Anne Dekeyne; Clotilde Mannoury La Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
Psychopharmacology 2008;199(4):549-68.
2008: Delphine S Dupuis; Clotilde Mannoury la Cour; Christine Chaput; Laurence Verrièle; Gilbert Lavielle; Mark J Millan
Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.
European journal of pharmacology 2008;588(2-3):170-7.
2008: Clotilde Mannoury La Cour; Chloé Herbelles; Valérie Pasteau; Guillaume De Nanteuil; Mark J Millan
Influence of positive allosteric modulators on GABA(B) receptor coupling in rat brain: a scintillation proximity assay characterisation of G protein subtypes.
Journal of neurochemistry 2008;105(2):308-23.
2008: Mark J Millan; Florence Loiseau; Anne Dekeyne; Alain Gobert; Gunnar Flik; Thomas I Cremers; Jean-Michel Rivet; Dorothée Sicard; Rodolphe Billiras; Mauricette Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
The Journal of pharmacology and experimental therapeutics 2008;324(3):1212-26.
2008: Mark J Millan; Clotilde Mannoury La Cour; Francesca Novi; Roberto Maggio; Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; Valérie Pasteau; Jean-A Boutin; T Dubuffet; Gilbert Lavielle
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):587-99.
2008: Mark J Millan; Per Svenningsson; Charles R Ashby; Michael Hill; Martin Egeland; Anne Dekeyne; Mauricette Brocco; Benjamin Di Cara; Françoise Lejeune; Nitza Thomasson; Carmen Munoz; Elisabeth Mocaër; Alan R Crossman; Laetitia Cistarelli; Sylvie Girardon; Loretta Iob; Sylvie Veiga; Alain Gobert
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
The Journal of pharmacology and experimental therapeutics 2008;324(2):600-11.
2008: Florence Loiseau; Anne Dekeyne; Mark J Millan
Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.
Psychopharmacology 2008;196(1):93-104.
2007: Mark J Millan; Anne Dekeyne
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007;10(5):579-93.
2007: Benjamin Di Cara; Fany Panayi; Alain Gobert; Anne Dekeyne; Dorothée Sicard; Lotte De Groote; Mark J Millan
Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007;10(3):383-99.
2007: Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Psychopharmacology 2007;191(3):767-82.
2007: Clotilde Mannoury La Cour; S Vidal; Valérie Pasteau; Didier Cussac; Mark J Millan
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists.
Neuropharmacology 2007;52(3):1003-14.
2007: Mark J Millan; Benjamin Di Cara; Anne Dekeyne; Fany Panayi; Lotte De Groote; Dorothée Sicard; Laetitia Cistarelli; Rodolphe Billiras; Alain Gobert
Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.
Journal of neurochemistry 2007;100(4):1047-61.
2006: Mauricette Brocco; Anne Dekeyne; Mariusz Papp; Mark J Millan
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Behavioural pharmacology 2006;17(7):559-72.
2006: Anne Dekeyne; Mark J Millan
Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin.
Neuropharmacology 2006;51(4):718-26.
2006: Anne Amphoux; Vincent Vialou; Eva Drescher; Michael Brüss; Clotilde Mannoury La Cour; Catherine Rochat; Mark J Millan; Bruno GIROS; Heinz Bönisch; Sophie Gautron
Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.
Neuropharmacology 2006;50(8):941-52.
2006: Mark J Millan
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
Pharmacology & therapeutics 2006;110(2):135-370.
2005: Mark J Millan
N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
Psychopharmacology 2005;179(1):30-53.
2004: Alain Gobert; Rodolphe Billiras; Laetitia Cistarelli; Mark J Millan
Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
Journal of neuroscience methods 2004;140(1-2):141-52.
2004: Mark J Millan; Alain Gobert; Sylvain Roux; Roger Porsolt; Alfredo Meneses; Mirjana Carli; Benjamin Di Cara; Robert Jaffard; Jean-Michel Rivet; Pierre Lestage; Elisabeth Mocaer; Jean-Louis Peglion; Anne Dekeyne
The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
The Journal of pharmacology and experimental therapeutics 2004;311(1):190-203.
2004: Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.
Psychopharmacology 2004;174(3):341-57.
2004: Mark J Millan; Mauricette Brocco; Mariusz Papp; Florence Serres; Christophe Drieu La Rochelle; Trevor Sharp; Jean-Louis Peglion; Anne Dekeyne
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):936-50.
2004: Mark J Millan; Benjamin Di Cara; Michael Hill; Michael Jackson; Jeffrey N. Joyce; Jonathan M Brotchie; Steve McGuire; Alan R Crossman; Lance Smith; Peter Jenner; Alain Gobert; Jean-Louis Peglion; Mauricette Brocco
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):921-35.
2004: Mark J Millan; Didier Cussac; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Clotilde Mannoury La Cour; Adrian Newman-Tancredi; Jean-Louis Peglion
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):903-20.
2004: Didier Cussac; Valérie Pasteau; Mark J Millan
Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine.
European journal of pharmacology 2004;485(1-3):111-7.
2003: Anne Dekeyne; Mark J Millan
Discriminative stimulus properties of antidepressant agents: a review.
Behavioural pharmacology 2003;14(5-6):391-407.
2003: Adrian Newman-Tancredi; Jean-Michel Rivet; Didier Cussac; Manuelle Touzard; C Chaput; Laetitia Marini; Mark J Millan
Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Naunyn-Schmiedeberg's archives of pharmacology 2003;368(3):188-99.
2003: Mark J Millan; Alain Gobert; Françoise Lejeune; Anne Dekeyne; Adrian Newman-Tancredi; Valérie Pasteau; Jean-Michel Rivet; Didier Cussac
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
The Journal of pharmacology and experimental therapeutics 2003;306(3):954-64.
2003: Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.
Psychopharmacology 2003;168(4):397-409.
2003: Anne Dekeyne; Loretta Iob; Mark J Millan
Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907.
Neuropharmacology 2003;44(5):604-15.
2003: Alain Gobert; Benjamin Di Cara; Laetitia Cistarelli; Mark J Millan
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
The Journal of pharmacology and experimental therapeutics 2003;305(1):338-46.
2003: Françoise Lejeune; Mark J Millan
The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats.
European journal of pharmacology 2003;464(2-3):127-33.
2003: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Manuelle Touzard; Mark J Millan
h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.
British journal of pharmacology 2003;138(6):1077-84.
2003: Mark J Millan; Mauricette Brocco
The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines.
European journal of pharmacology 2003;463(1-3):67-96.
2002: Adrian Newman-Tancredi; Didier Cussac; Yann Quentric; Manuelle Touzard; Laurence Verrièle; Nathalie Carpentier; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):815-22.
2002: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean A Boutin; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
The Journal of pharmacology and experimental therapeutics 2002;303(2):805-14.
2002: Mark J Millan; Lisa Maiofiss; Didier Cussac; Valérie Audinot; Jean A Boutin; Adrian Newman-Tancredi
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):791-804.
2002: Valérie Audinot; Nelly Fabry; Jean-Paul Nicolas; Philippe Beauverger; Adrian Newman-Tancredi; Mark J Millan; Anne Try; Frédéric Bornancin; Emmanuel Canet; Jean A Boutin
Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors.
Cellular signalling 2002;14(10):829-37.
2002: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Mark J Millan
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
Molecular pharmacology 2002;62(3):590-601.
2002: Didier Cussac; Adrian Newman-Tancredi; Delphine Duqueyroix; Valérie Pasteau; Mark J Millan
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Molecular pharmacology 2002;62(3):578-89.
2002: Didier Cussac; Delphine Duqueyroix; Adrian Newman-Tancredi; Mark J Millan
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Psychopharmacology 2002;162(2):168-77.
2002: Anne Dekeyne; Alain Gobert; Agnès Auclair; Sylvie Girardon; Mark J Millan
Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.
Psychopharmacology 2002;162(2):156-67.
2002: Françoise Lejeune; Alain Gobert; Mark J Millan
The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study.
Brain research 2002;935(1-2):134-9.
2002: Mark J Millan
Descending control of pain.
Progress in neurobiology 2002;66(6):355-474.
2002: Mark J Millan; Sylvie Girardon; J Mullot; Mauricette Brocco; Anne Dekeyne
Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists.
Neuropharmacology 2002;42(5):677-84.
2002: Anne Dekeyne; Loretta Iob; Patrick Hautefaye; Mark J Millan
The selective serotonin(2A) receptor antagonist, MDL100,907, elicits a specific interoceptive cue in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(4):552-6.
2002: Mauricette Brocco; Anne Dekeyne; Sylvie Veiga; Sylvie Girardon; Mark J Millan
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
Pharmacology, biochemistry, and behavior 2002;71(4):667-80.
2002: Mark J Millan; Adrian Newman-Tancredi; S Lochon; Manuelle Touzard; S Aubry; Valérie Audinot
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
Pharmacology, biochemistry, and behavior 2002;71(4):589-98.
2002: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Nathalie Carpentier; Guillaume Poissonnet; Jean-Gilles Parmentier; Solo Goldstein; Mark J Millan
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(3):242-52.
2002: Jean-Louis Peglion; Bertrand Goument; Nicole Despaux; Valérie Charlot; Hélène Giraud; Christian Nisole; Adrian Newman-Tancredi; Anne Dekeyne; Marc Bertrand; Patrick Genissel; Mark J Millan
Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.
Journal of medicinal chemistry 2002;45(1):165-76.
2001: Adrian Newman-Tancredi; Didier Cussac; Mauricette Brocco; Jean-Michel Rivet; C Chaput; Manuelle Touzard; Valérie Pasteau; Mark J Millan
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra.
Brain research 2001;920(1-2):41-54.
2001: Anne Dekeyne; Alain Gobert; Loretta Iob; Laetitia Cistarelli; C Melon; Mark J Millan
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
Psychopharmacology 2001;158(2):213-8.
2001: Adrian Newman-Tancredi; Laurence Verrièle; Manuelle Touzard; Mark J Millan
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
European journal of pharmacology 2001;428(2):177-84.
2001: Mark J Millan; Mauricette Brocco; Alain Gobert; G Dorey; Patrick J Casara; Anne Dekeyne
Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(4):585-600.
2001: Mark J Millan; Anne Dekeyne; Mariusz Papp; Christophe Drieu La Rochelle; Cliona MacSweeney; Jean-Louis Peglion; Mauricette Brocco
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
The Journal of pharmacology and experimental therapeutics 2001;298(2):581-91.
2001: Mark J Millan; Alain Gobert; Françoise Lejeune; Adrian Newman-Tancredi; Jean-Michel Rivet; Agnès Auclair; Jean-Louis Peglion
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
The Journal of pharmacology and experimental therapeutics 2001;298(2):565-80.
2001: Mark J Millan; Adrian Newman-Tancredi; Delphine Duqueyroix; Didier Cussac
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
European journal of pharmacology 2001;424(1):13-7.
2001: Mark J Millan; Adrian Newman-Tancredi; Yann Quentric; Didier Cussac
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors.
Psychopharmacology 2001;156(1):58-62.
2001: Mark J Millan; Didier Cussac; G Milligan; C Carr; Valérie Audinot; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Mauricette Brocco; Delphine Duqueyroix; Jean-Paul Nicolas; Jean A Boutin; Adrian Newman-Tancredi
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
The Journal of pharmacology and experimental therapeutics 2001;297(3):876-87.
2001: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Mark J Millan
Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(4):391-8.
2001: Alex Cordi; I Berque-Bestel; T Persigand; Jean-Michel Lacoste; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
Journal of medicinal chemistry 2001;44(5):787-805.
2001: Mark J Millan; F Lejeune; G De Nanteuil; Alain Gobert
Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats.
Journal of neurochemistry 2001;76(6):1949-54.
2001: Graeme Milligan; Elaine Kellett; Catherine Dacquet; V Dubreuil; E Jacoby; Mark J Millan; Gilbert Lavielle; Michael Spedding
S 14506: novel receptor coupling at 5-HT(1A) receptors.
Neuropharmacology 2001;40(3):334-44.
2001: Anne Dekeyne; Loretta Iob; Mark J Millan
Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats.
Psychopharmacology 2001;153(3):389-92.
2001: Adrian Newman-Tancredi; Laurence Verrièle; Mark J Millan
Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
British journal of pharmacology 2001;132(2):518-24.
2001: Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms.
Neuropharmacology 2001;40(1):57-64.
2000: Mark J Millan; Françoise Lejeune; Alain Gobert; Mauricette Brocco; Agnès Auclair; C Bosc; Jean-Michel Rivet; Jean-Michel Lacoste; Alex Cordi; Anne Dekeyne
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1206-22.
2000: Mark J Millan; Anne Dekeyne; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; G Milligan; Delphine Duqueyroix; Sylvie Girardon; J Mullot; Jean A Boutin; Jean-Paul Nicolas; A Renouard-Try; Jean-Michel Lacoste; Alex Cordi
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1192-205.
2000: Mark J Millan
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
The Journal of pharmacology and experimental therapeutics 2000;295(3):853-61.
2000: Adrian Newman-Tancredi; Valérie Audinot; C Moreira; Laurence Verrièle; Mark J Millan
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
Molecular pharmacology 2000;58(5):1042-9.
2000: Anne Dekeyne; Mauricette Brocco; A Adhumeau; Alain Gobert; Mark J Millan
The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
Psychopharmacology 2000;152(1):55-66.
2000: Françoise Lejeune; Mark J Millan
Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors.
The European journal of neuroscience 2000;12(9):3265-75.
2000: Alain Gobert; Anne Dekeyne; Mark J Millan
The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572.
Neuropharmacology 2000;39(9):1608-16.
2000: Mark J Millan; F Lejeune; Alain Gobert
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents.
Journal of psychopharmacology (Oxford, England) 2000;14(2):114-38.
2000: Mark J Millan; Anne Dekeyne; Jean-Michel Rivet; T Dubuffet; Gilbert Lavielle; Mauricette Brocco
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1063-73.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; T Dubuffet; Gilbert Lavielle
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1048-62.
2000: Alain Gobert; Jean-Michel Rivet; Françoise Lejeune; Adrian Newman-Tancredi; A Adhumeau-Auclair; Jean-Paul Nicolas; Laetitia Cistarelli; C Melon; Mark J Millan
Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Synapse (New York, N.Y.) 2000;36(3):205-21.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):569-72.
2000: Didier Cussac; Adrian Newman-Tancredi; J P Nicolas; J A Boutin; Mark J Millan
Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):549-54.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
European journal of pharmacology 2000;394(1):47-50.
2000: Anne Dekeyne; B Denorme; S Monneyron; Mark J Millan
Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors.
Neuropharmacology 2000;39(6):1114-7.
2000: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Mark J Millan
[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum.
Neuropharmacology 2000;39(6):1111-3.
2000: Brian J Morris; Adrian Newman-Tancredi; V Audinot; CS Simpson; Mark J Millan
Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons.
Journal of neuroscience research 2000;59(6):740-9.
2000: Mark J Millan; Alain Gobert; Jean-Michel Rivet; A Adhumeau-Auclair; Didier Cussac; Adrian Newman-Tancredi; Anne Dekeyne; Jean-Paul Nicolas; Françoise Lejeune
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
The European journal of neuroscience 2000;12(3):1079-95.
2000: Mark J Millan; Sylvie Girardon; S Monneyron; Anne Dekeyne
Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
Neuropharmacology 2000;39(4):586-98.
2000: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Mark J Millan
An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(2):221-3.
2000: Mark J Millan; Alain Gobert; K Bervoets; Jean-Michel Rivet; Sylvie Veiga; Mauricette Brocco
Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 2000;292(2):672-83.
2000: Mark J Millan; Adrian Newman-Tancredi; Valérie Audinot; Didier Cussac; Françoise Lejeune; Jean-Paul Nicolas; Francis Cogé; Jean-Pierre Galizzi; Jean A Boutin; Jean-Michel Rivet; Anne Dekeyne; Alain Gobert
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Synapse (New York, N.Y.) 2000;35(2):79-95.
2000: Mark J Millan; Valérie Audinot; P Honoré; K Bervoets; Sylvie Veiga; Mauricette Brocco
Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats.
European journal of pharmacology 2000;388(1):37-47.
2000: Mark J Millan; Mauricette Brocco; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; L Maiofiss; S Queriaux; Nicole Despaux; Jean-Louis Peglion; Anne Dekeyne
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 2000;292(1):54-66.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; A Adhumeau; Mauricette Brocco; Jean-Paul Nicolas; Jean A Boutin; Nicole Despaux; Jean-Louis Peglion
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
The Journal of pharmacology and experimental therapeutics 2000;292(1):38-53.
1999: Mark J Millan; Mauricette Brocco; Alain Gobert; F Joly; K Bervoets; Jean-Michel Rivet; Adrian Newman-Tancredi; Valérie Audinot; S Maurel
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.
The European journal of neuroscience 1999;11(12):4419-32.
1999: Adrian Newman-Tancredi; Jean-Michel Rivet; C Chaput; Manuelle Touzard; Laurence Verrièle; Mark J Millan
The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study.
European journal of pharmacology 1999;384(2-3):111-21.
1999: Claude Sebban; Brigitte Tesolin-Decros; Mark J Millan; Michael Spedding
Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil.
British journal of pharmacology 1999;128(5):1055-63.
1999: Claude Sebban; X Q Zhang; Brigitte Tesolin-Decros; Mark J Millan; Michael Spedding
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission.
British journal of pharmacology 1999;128(5):1045-54.
1999: Didier Cussac; Adrian Newman-Tancredi; Valérie Pasteau; Mark J Millan
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism.
Molecular pharmacology 1999;56(5):1025-30.
1999: Mark J Millan; Alain Gobert; Valérie Audinot; Anne Dekeyne; Adrian Newman-Tancredi
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2 Suppl):61S-67S.
1999: Alain Gobert; Mark J Millan
Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2):268-84.
1999: T Dubuffet; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; A Loutz; Mark J Millan; Gilbert Lavielle
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters 1999;9(14):2059-64.
1999: Mark J Millan; Alain Gobert
(-)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats.
Neuropharmacology 1999;38(6):909-12.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Mark J Millan
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):447-53.
1999: Mark J Millan; rudy schreiber; S Monneyron; B Denorme; C Melon; S Queriaux; Anne Dekeyne
S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine.
The Journal of pharmacology and experimental therapeutics 1999;289(1):427-36.
1999: Mark J Millan; Sylvie Girardon; Anne Dekeyne
5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats.
Psychopharmacology 1999;142(4):432-4.
1999: Anne Dekeyne; Sylvie Girardon; Mark J Millan
Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis.
Neuropharmacology 1999;38(3):415-23.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Valérie Pasteau; S Gavaudan; Mark J Millan
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Molecular pharmacology 1999;55(3):564-74.
1999: Mark J Millan; Mauricette Brocco; Alain Gobert; rudy schreiber; Anne Dekeyne
S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1999;288(3):1002-14.
1999: Alain Gobert; Mark J Millan
Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats.
Neuropharmacology 1999;38(2):315-7.
1999: Mark J Millan; Alain Gobert; Sylvie Girardon; Anne Dekeyne
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
European journal of pharmacology 1999;364(2-3):147-50.
1999: Alain Gobert; Jean-Michel Rivet; Laetitia Cistarelli; C Melon; Mark J Millan
Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.
Neuroscience 1999;93(4):1251-62.
1999: Mark J Millan
The induction of pain: an integrative review.
Progress in neurobiology 1999;57(1):1-164.
1998: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Laurence Verrièle; Mark J Millan
Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535.
Annals of the New York Academy of Sciences 1998;861():263-4.
1998: Valérie Audinot; Adrian Newman-Tancredi; Alain Gobert; Jean-Michel Rivet; Mauricette Brocco; Françoise Lejeune; L Gluck; I Desposte; K Bervoets; Anne Dekeyne; Mark J Millan
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
The Journal of pharmacology and experimental therapeutics 1998;287(1):187-97.
1998: Mark J Millan; Adrian Newman-Tancredi; Mauricette Brocco; Alain Gobert; Françoise Lejeune; Valérie Audinot; Jean-Michel Rivet; rudy schreiber; Anne Dekeyne; Michael Spedding; Jean-Paul Nicolas; Jean-Louis Peglion
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
The Journal of pharmacology and experimental therapeutics 1998;287(1):167-86.
1998: Françoise Lejeune; Mark J Millan
Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
Synapse (New York, N.Y.) 1998;30(2):172-80.
1998: Mark J Millan; rudy schreiber; Anne Dekeyne; Jean-Michel Rivet; K Bervoets; M Mavridis; Claude Sebban; S Maurel-Remy; Adrian Newman-Tancredi; Michael Spedding; O Muller; Gilbert Lavielle; Mauricette Brocco
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1356-73.
1998: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Valérie Audinot; Françoise Lejeune; Jean-Michel Rivet; Didier Cussac; Jean-Paul Nicolas; O Muller; Gilbert Lavielle
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1341-55.
1998: Adrian Newman-Tancredi; S Gavaudan; C Conte; C Chaput; Manuelle Touzard; Laurence Verrièle; Valérie Audinot; Mark J Millan
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
European journal of pharmacology 1998;355(2-3):245-56.
1998: Adrian Newman-Tancredi; Jean-Paul Nicolas; Valérie Audinot; S Gavaudan; Laurence Verrièle; Manuelle Touzard; C Chaput; N Richard; Mark J Millan
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1998;358(2):197-206.
1998: Mark J Millan; Anne Dekeyne; Alain Gobert
Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.
Neuropharmacology 1998;37(7):953-5.
1998: Michael Spedding; Adrian Newman-Tancredi; Mark J Millan; Catherine Dacquet; A N Michel; E Jacoby; B Vickery; D Tallentire
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat.
Neuropharmacology 1998;37(6):769-80.
1998: Alain Gobert; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Laetitia Cistarelli; Mark J Millan
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.
Neuroscience 1998;84(2):413-29.
1998: Adrian Newman-Tancredi; C Chaput; S Gavaudan; Laurence Verrièle; Mark J Millan
Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;18(5):395-8.
1998: Adrian Newman-Tancredi; Laurence Verrièle; C Chaput; Mark J Millan
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
Naunyn-Schmiedeberg's archives of pharmacology 1998;357(3):205-17.
1998: Mark J Millan; Mauricette Brocco; Sylvie Veiga; Laetitia Cistarelli; C Melon; Alain Gobert
WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex.
European journal of pharmacology 1998;341(2-3):165-7.
1998: Mark J Millan
Alpha 2-adrenergic mechanisms of analgesia: strategies for improving their therapeutic window and identification of the novel, potent alpha 2A-adrenergic receptor agonist, S 18616.
Advances in pharmacology (San Diego, Calif.) 1998;42():575-9.
1997: Alain Gobert; Jean-Michel Rivet; Laetitia Cistarelli; C Melon; Mark J Millan
Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
Journal of neurochemistry 1997;69(6):2616-9.
1997: Adrian Newman-Tancredi; Valérie Audinot; C Chaput; Laurence Verrièle; Mark J Millan
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 1997;282(1):181-91.
1997: Mark J Millan; Stephan Hjorth; R Samanin; rudy schreiber; Robert Jaffard; B De Ladonchamps; Sylvie Veiga; B Goument; Jean-Louis Peglion; Michael Spedding; Mauricette Brocco
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
The Journal of pharmacology and experimental therapeutics 1997;282(1):148-61.
1997: Mark J Millan; Adrian Newman-Tancredi; Jean-Michel Rivet; Mauricette Brocco; P Lacroix; Valérie Audinot; Laetitia Cistarelli; Alain Gobert
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
The Journal of pharmacology and experimental therapeutics 1997;282(1):132-47.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; Laurence Verrièle; V Audinot-Bouchez; S Lochon; Gilbert Lavielle; Mark J Millan
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Naunyn-Schmiedeberg's archives of pharmacology 1997;355(6):682-8.
1997: Valérie Audinot; S Lochon; Adrian Newman-Tancredi; Gilbert Lavielle; Mark J Millan
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine.
European journal of pharmacology 1997;327(2-3):247-56.
1997: Mark J Millan; Jean-Louis Peglion; Gilbert Lavielle; S Perrin-Monneyron
5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists.
European journal of pharmacology 1997;325(1):9-12.
1997: Mark J Millan; Sylvie Girardon; K Bervoets
8-OH-DPAT-induced spontaneous tail-flicks in the rat are facilitated by the selective serotonin (5-HT)2C agonist, RO 60-0175: blockade of its actions by the novel 5-HT2C receptor antagonist SB 206,553.
Neuropharmacology 1997;36(4-5):743-5.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; Laurence Verrièle; Mark J Millan
Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry.
Neuropharmacology 1997;36(4-5):451-9.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; M Spedding; Mark J Millan
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635.
British journal of pharmacology 1997;120(5):737-9.
1997: Françoise Lejeune; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1241-9.
1997: Alain Gobert; Jean-Michel Rivet; J M Cistarelli; Mark J Millan
Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats.
Journal of neurochemistry 1997;68(3):1326-9.
1997: Alain Gobert; Jean-Michel Rivet; Laetitia Cistarelli; Mark J Millan
Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935.
Journal of neurochemistry 1997;68(3):1159-63.
1997: Adrian Newman-Tancredi; V Audinot-Bouchez; Alain Gobert; Mark J Millan
Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors.
European journal of pharmacology 1997;319(2-3):379-83.
1996: Adrian Newman-Tancredi; C Chaput; Laurence Verrièle; Mark J Millan
S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
European journal of pharmacology 1996;307(1):107-11.
1996: Alain Gobert; F Lejeune; Jean-Michel Rivet; Laetitia Cistarelli; Mark J Millan
Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo.
Journal of neurochemistry 1996;66(5):2209-12.
1996: Adrian Newman-Tancredi; Laurence Verrièle; C Chaput; Mark J Millan
Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation.
Brain research bulletin 1996;41(2):93-6.
1996: Mark J Millan; L Seguin; P Honoré; Sylvie Girardon; K Bervoets
Pro- and antinociceptive actions of serotonin (5-HT)1A agonists and antagonists in rodents: relationship to algesiometric paradigm.
Behavioural brain research 1996;73(1-2):69-77.
1996: Adrian Newman-Tancredi; C Chaput; L Verriele; Mark J Millan
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.
Neuropharmacology 1996;35(1):119-21.
1995: Adrian Newman-Tancredi; Valérie Audinot; V Jacques; Jean-Louis Peglion; Mark J Millan
[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.
Neuropharmacology 1995;34(12):1693-6.
1995: Alain Gobert; Jean-Michel Rivet; Valérie Audinot; Laetitia Cistarelli; Michael Spedding; J Vian; Jean-Louis Peglion; Mark J Millan
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
The Journal of pharmacology and experimental therapeutics 1995;275(2):899-913.
1995: Mark J Millan; Jean-Louis Peglion; J Vian; Jean-Michel Rivet; Mauricette Brocco; Alain Gobert; Adrian Newman-Tancredi; Catherine Dacquet; K Bervoets; Sylvie Girardon
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
The Journal of pharmacology and experimental therapeutics 1995;275(2):885-98.
1995: R Schreiber; M Brocco; B Lefèbvre de Ladonchamps; S Monneyron; Mark J Millan
A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin.
The Journal of pharmacology and experimental therapeutics 1995;275(2):822-31.
1995: Jean-Louis Peglion; H Canton; K Bervoets; Valérie Audinot; Mauricette Brocco; Alain Gobert; S Le Marouille-Girardon; Mark J Millan
Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.
Journal of medicinal chemistry 1995;38(20):4044-55.
1995: Mark J Millan; Valérie Audinot; C Melon; Adrian Newman-Tancredi
Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia.
European journal of pharmacology 1995;280(2):225-9.
1995: S Maurel-Remy; K Bervoets; Mark J Millan
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors.
European journal of pharmacology 1995;280(2):R9-11.
1995: Mark J Millan; Jean-Michel Rivet; Valérie Audinot; Alain Gobert; Françoise Lejeune; Mauricette Brocco; Adrian Newman-Tancredi; S Maurel-Remy; K Bervoets
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1418-27.
1995: Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1032-46.
1995: rudy schreiber; Mauricette Brocco; B L de Ladonchamps; Mark J Millan
Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test.
Pharmacology, biochemistry, and behavior 1995;51(2-3):211-5.
1995: L Seguin; S Le Marouille-Girardon; Mark J Millan
Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent.
Pain 1995;61(2):325-43.
1995: rudy schreiber; Mauricette Brocco; Valérie Audinot; Alain Gobert; Sylvie Veiga; Mark J Millan
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
The Journal of pharmacology and experimental therapeutics 1995;273(1):101-12.
1995: Françoise Lejeune; Mark J Millan
Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo.
European journal of pharmacology 1995;275(3):R7-9.
1994: rudy schreiber; Mauricette Brocco; Alain Gobert; Sylvie Veiga; Mark J Millan
The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists.
European journal of pharmacology 1994;271(2-3):537-41.
1994: Jean-Michel Rivet; Valérie Audinot; Alain Gobert; Jean-Louis Peglion; Mark J Millan
Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297.
European journal of pharmacology 1994;265(3):175-7.
1994: H Canton; L Verrièle; Mark J Millan
Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics.
Neuroscience letters 1994;181(1-2):65-8.
1994: rudy schreiber; Mauricette Brocco; Mark J Millan
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.
European journal of pharmacology 1994;264(1):99-102.
1994: F Lejeune; Alain Gobert; Jean-Michel Rivet; Mark J Millan
Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones.
Brain research 1994;656(2):427-31.
1994: Mark J Millan; K Bervoets; Jean-Michel Rivet; P Widdowson; A Renouard; S Le Marouille-Girardon; Alain Gobert
Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline.
The Journal of pharmacology and experimental therapeutics 1994;270(3):958-72.
1994: A Renouard; P S Widdowson; Mark J Millan
Multiple alpha 2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002-labeled rat R alpha-2A adrenergic receptors in cerebral cortex to human H alpha2A adrenergic receptor and other populations of alpha-2 adrenergic subtypes.
The Journal of pharmacology and experimental therapeutics 1994;270(3):946-57.
1994: Mark J Millan; L Seguin
Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice.
Neuroscience letters 1994;178(1):139-43.
1994: Mark J Millan; Valérie Audinot; Jean-Michel Rivet; Alain Gobert; J Vian; J F Prost; Michael Spedding; Jean-Louis Peglion
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats.
European journal of pharmacology 1994;260(2-3):R3-5.
1994: Mark J Millan; Jean-Michel Rivet; Alain Gobert; H Canton; Sylvie Veiga; K Bervoets
5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm.
The Journal of pharmacology and experimental therapeutics 1994;269(1):121-31.
1994: Mark J Millan; H Canton; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; K Bervoets; Mauricette Brocco; P Widdowson; T Mennini; Valérie Audinot
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
The Journal of pharmacology and experimental therapeutics 1994;268(1):337-52.
1993: Françoise Lejeune; Jean-Michel Rivet; Alain Gobert; H Canton; Mark J Millan
WAY 100,135 and (-)-tertatolol act as antagonists at both 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors in vivo.
European journal of pharmacology 1993;240(2-3):307-10.
1993: Mark J Millan; Jean-Michel Rivet; H Canton; S Le Marouille-Girardon; Alain Gobert
Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.
The Journal of pharmacology and experimental therapeutics 1993;264(3):1364-76.
1993: Mark J Millan; Jean-Michel Rivet; H Canton; Françoise Lejeune; Alain Gobert; P Widdowson; K Bervoets; Mauricette Brocco; Jean-Louis Peglion
S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively.
European journal of pharmacology 1993;230(1):99-102.
1993: K Bervoets; Jean-Michel Rivet; Mark J Millan
5-HT1A receptors and the tail-flick response. IV. Spinally localized 5-HT1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat.
The Journal of pharmacology and experimental therapeutics 1993;264(1):95-104.
1992: Mark J Millan; Jean-Michel Rivet; H Canton; Françoise Lejeune; K Bervoets; Mauricette Brocco; Alain Gobert; B Lefebvre de Ladonchamps; S Le Marouille-Girardon; L Verriele
S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
The Journal of pharmacology and experimental therapeutics 1992;262(2):451-63.
1991: M Mavridis; F C Colpaert; Mark J Millan
Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists.
Brain research 1991;562(2):216-24.
1991: Mark J Millan; H Canton; Jean-Michel Rivet; Françoise Lejeune; Michel Laubie; Gilbert Lavielle
S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potency.
European journal of pharmacology 1991;203(2):319-22.
1991: Mark J Millan; K Bervoets; M Mavridis
The serotonin (5-HT)1A agonist, LY 165,163, induces contralateral rotation in unilateral substantia nigra-lesioned rats via dopamine receptors.
Neuroscience letters 1991;130(2):173-6.